Korea Business News Agency - NSP NEWS AGENCY.

(Seoul=NSP News Agency) eunyoung Huh Journalist = SK began to expand its capacity of its CDMO(Contract Development & Manufacturing Organization) to produce pharmaceutical ingredient at home and its reach further to the global market.

SK Biotek - a subsidiary of SK Pharmteco, a global CDMO (contract development and manufacturing organization) joint corporation, wholly owned by SK Inc. - has recently added new plants in its Sejong Complex started operation in September.

SK Biotek has recently built additional production facilities as large as 290㎥, more than 50 percent bigger than the previous size of 190㎥, which can produce 150 tons of pharmaceutical ingredients every year.

Over the last two years, SK Biotek has invested about 56 billion won to construct M3 plant. With the expansion of production capacity, SK Biotek will see an increase in yearly sales by more than 1.5 times, from 150 billion won to 220 billion won.

SK Pharmteco, a CDMO joint corporation, recorded 830 billion won in sales last year, ranking as a global top 5 synthetic drug CDMO. When more constructions ongoing in the US and Ireland are completed, the annual revenue of SK Pharmteco and SK Biotek is forecast to surpass 1 trillion won in 2 to 3 years.

“Once the construction of the M4 plant is completed, our production capacity will be expanded to 400 ㎥ in the latter half of next year, and we will continue to move forward to become a global CDMO,” said CEO of SK Biotek.

NSP News Agency eunyoung Huh Journalist eunyoung114@nspna.com
Copyright ⓒ Korea's economic news agency NSP NEWS·NSP TV. All rights reserved-Redistribution Prohibited.